The identification of the mobile receptor utilized by viruses to enter their goal cells is all the time a problem and so far entry receptors stay to be recognized for quite a lot of pathogenic human viruses. Human T-lymphotropic virus sort 1 (HTLV-1), the distinctive oncogenic retrovirus in human, was recognized within the early 1980 ‘s.
The character of its entry receptor has remained a thriller for over 20 years, till the unbiased identification of three proteins presenting the anticipated standards, the glucose transporter Glut1, Neuropilin 1, a VEGF receptor, and heparan sulfate proteoglycans. On this overview, we summarize the information pertaining to HTLV-1 entry molecules and current a brand new mannequin, during which these three proteins successively intervene in the course of the entry course of.
Protecting efficacy of rhesus adenovirus COVID-19 vaccines in opposition to mouse-adapted SARS-CoV-2
The speedy design and implementation of extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is testomony to a efficiently coordinated international analysis effort. Whereas using quite a lot of totally different applied sciences, a few of which have been used for the primary time, all authorized vaccines show excessive ranges of efficacy with glorious security profiles.
Regardless of this, there stays an pressing international demand for coronavirus illness 2019 vaccines that require additional candidates to move part three medical trials. Within the expectation of SARS-CoV-2 changing into endemic, researchers want to alter the vaccine constructs to sort out rising variants.
On this overview, we define totally different platforms used for authorized vaccines and summarize newest analysis information close to immunogenicity, dosing regimens and effectivity in opposition to rising variants.

A Multiplex Noninvasive Salivary Antibody Assay for SARS-CoV-2 An infection and Its Utility in a Inhabitants-Primarily based Survey by Mail
Noninvasive salivary antibody immunoassays can allow low-cost epidemiological surveillance of infections. This research concerned growing and validating a multiplex suspension immunoassay on the Luminex platform to measure immunoglobulin G (IgG) responses to extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid and spike (S) proteins, and the spike protein’s S1 and S2 subunits and receptor binding area.
A number of variations of those recombinant proteins acquired from industrial and noncommercial sources have been evaluated. Assay improvement and validation utilized saliva and serum samples from coronavirus illness 2019 (COVID-19) circumstances procured from industrial sources and adverse controls from a prepandemic survey.
Saliva was additionally collected in an indication survey by mail involving grownup people in america who have been recognized with SARS-CoV-2 an infection 15 to 80 days previous to pattern assortment. The survey had an 83% legitimate pattern return price (192 samples from 38 states). Most COVID-19 circumstances (93%) reported mildly symptomatic or asymptomatic infections.
The ultimate salivary assay based mostly on the best-performing spike and nucleocapsid proteins had a sensitivity of 87.1% (95% bootstrap confidence interval, 82.1 to 91.7%) and specificity of 98.5% (95.Zero to 100%) utilizing 227 and 285 saliva samples, respectively.
The identical assay had 95.9% (92.eight to 98.9%) sensitivity and 100% (98.four to 100%) specificity in serum (174 and 285 serum samples, respectively). Salivary and serum antibody responses to spike and nucleocapsid proteins have been strongly correlated in 22 paired samples (r = 0.88 and r = 0.80, respectively).
Antibody responses peaked at roughly 50 days postonset; better sickness severity was related to stronger responses. This research demonstrated {that a} salivary antibody assay can be utilized in large-scale inhabitants surveys by mail to raised characterize public well being impacts of COVID-19. IMPORTANCE Given the large impacts of the COVID-19 pandemic, growing instruments for inhabitants surveillance of an infection is of paramount significance.
This text describes the event of a multiplex immunoassay on a Luminex platform to measure salivary immunoglobulin G responses to the spike protein, its two subunits and receptor binding area, and the nucleocapsid protein of SARS-CoV-2. The assay validation utilized serum and saliva samples from prepandemic controls and up to date COVID-19 circumstances.
A survey by mail focusing on latest COVID-19 circumstances throughout america additionally demonstrated the utility of protected, at-home self-collection of saliva. By incorporating a number of SARS-CoV-2 proteins, this assay might differentiate responses to pure SARS-CoV-2 infections from responses to most vaccines.
Utility of this noninvasive immunoassay in COVID-19 surveillance can assist present estimates of cumulative incidence charges of symptomatic and asymptomatic infections in numerous communities and subpopulations, temporal patterns of antibody responses, and threat components for an infection.
Uncared for roles of IgG Fc-binding protein secreted from airway mucin-producing cells in defending in opposition to SARS-CoV-2 an infection
Each innate immunity and purchased immunity are concerned in extreme acute respiratory syndrome coronavirus-2 (SARS-CoV-2) an infection. The induction of Abs that neutralize the virus has been described, and sure Abs in opposition to endemic coronaviruses might cross-react with SARS-CoV-2. Detailed mechanisms to guard in opposition to the pandemic of SARS-CoV-2 stay unresolved.
We beforehand reported that IgG Fc-binding protein (Fcγbp), a novel, massive molecular weight, and mucin-like secretory Fc receptor protein, secreted from goblet cells of human small and enormous gut, mediates the transportation of serum IgG onto the mucosal floor.
On this overview, we present that mucous bronchial gland cells and a few goblet cells are immunoreactive for Fcγbp. Fcγbp traps the cross-reactive (each neutralizing and non-neutralizing) IgG certain to the virus and may consequently remove the virus from the mucosal floor to lower viral hundreds.
Fcγbp may suppress immune overreaction by interfering with Fc-binding by macrophages and competing with complement fixation. Fcγbp secreted from mucin-producing cells of the airway capabilities as an necessary anti-infection mucosal protection. The Fcγbp-mediated mechanism could be a key think about explaining why SARS-CoV-2 is much less infective/deadly in youngsters, and may be concerned within the distinctive Ab response, recurrent an infection, and results of serum remedy and vaccination.
Protecting efficacy of rhesus adenovirus COVID-19 vaccines in opposition to mouse-adapted SARS-CoV-2
The worldwide COVID-19 pandemic has sparked intense curiosity within the speedy improvement of vaccines in addition to animal fashions to guage vaccine candidates and to outline immune correlates of safety. We lately reported a mouse-adapted SARS-CoV-2 virus pressure (MA10) with the potential to contaminate wild-type laboratory mice, driving excessive ranges of viral replication in respiratory tract tissues in addition to extreme medical and respiratory signs, points of COVID-19 illness in people which are necessary to seize in mannequin techniques.
We evaluated the immunogenicity and protecting efficacy of novel rhesus adenovirus serotype 52 (RhAd52) vaccines in opposition to MA10 problem in mice. Baseline seroprevalence is decrease for rhesus adenovirus vectors than for human or chimpanzee adenovirus vectors, making these vectors enticing candidates for vaccine improvement.
We noticed that RhAd52 vaccines elicited sturdy binding and neutralizing antibody titers, which inversely correlated with viral replication after problem. These information help the event of RhAd52 vaccines and the usage of the MA10 problem virus to display screen novel vaccine candidates and to review the immunologic mechanisms that underscore safety from SARS-CoV-2 problem in wild-type mice.
Significance We have now developed a sequence of SARS-CoV-2 vaccines utilizing rhesus adenovirus serotype 52 (RhAd52) vectors, which reveals a decrease seroprevalence than human and chimpanzee vectors, supporting their improvement as novel vaccine vectors or in its place Advert vector for enhancing.
We sought to check these vaccines utilizing a lately reported mouse-adapted SARS-CoV-2 (MA10) virus to i) consider the protecting efficacy of RhAd52 vaccines and ii) additional characterize this mouse-adapted problem mannequin and probe immune correlates of safety.
SARS N Protein Antibody |
|
abx018255-100ug |
Abbexa |
100 ug |
EUR 460.8 |
|
|
SARS N Protein Antibody |
|
abx018255-1ml |
Abbexa |
1 ml |
EUR 300 |
SARS N Protein Antibody |
|
abx018256-100ug |
Abbexa |
100 ug |
EUR 460.8 |
|
|
SARS N Protein Antibody |
|
abx018256-1ml |
Abbexa |
1 ml |
EUR 300 |
SARS E protein Antibody |
|
GWB-62FEC0 |
GenWay Biotech |
0.05 mg |
Ask for price |
SARS N Protein Antibody |
|
E559506-5-PU |
EnoGene |
100ug |
EUR 295 |
|
Description: Available in various conjugation types. |
SARS N Protein Antibody |
|
E559506-6-PU |
EnoGene |
100ug |
EUR 295 |
|
Description: Available in various conjugation types. |
SARS N Protein Antibody |
|
MBS855000-01mg |
MyBiosource |
0.1mg |
EUR 370 |
SARS N Protein Antibody |
|
MBS855000-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
SARS N Protein Antibody |
|
MBS855000-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
SARS N Protein Antibody |
|
MBS855000-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
SARS N Protein Antibody |
|
MBS855000-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
SARS N Protein Antibody |
|
MBS855269-01mg |
MyBiosource |
0.1mg |
EUR 370 |
SARS N Protein Antibody |
|
MBS855269-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
SARS N Protein Antibody |
|
MBS855269-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
SARS N Protein Antibody |
|
MBS855269-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
SARS N Protein Antibody |
|
MBS855269-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
SARS-CoV-2 Spike Protein (S Protein) Polyclonal Antibody |
|
EGVR1001 |
EnoGene |
2019-nCoV-rabbit-polyclonal-antibody |
EUR 276.5 |
|
Description: 2019-nCoV rabbit polyclonal antibody |
SARS-CoV-2 Spike Protein (S Protein) Polyclonal Antibody |
|
MBS8574969-01mg |
MyBiosource |
0.1mg |
EUR 475 |
SARS-CoV-2 Spike Protein (S Protein) Polyclonal Antibody |
|
MBS8574969-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1985 |
SARS-Spike protein, Polyclonal Antibody (SARS-Spike Antibody) |
|
PT_72366 |
Novatein Biosciences, Inc. |
-
Ask for price
-
Ask for price
-
Ask for price
|
|
SARS-Nucleocapsid protein, Polyclonal Antibody (SARS-Nucleocapsid Antibody) |
|
PT_72368 |
Novatein Biosciences, Inc. |
-
Ask for price
-
Ask for price
-
Ask for price
|
|
SARS-Nucleocapsid protein, Monoclonal Antibody (SARS-Nucleocapsid Antibody) |
|
PT_72369 |
Novatein Biosciences, Inc. |
-
Ask for price
-
Ask for price
|
|
SARS-CoV-2 S Protein Mouse Monoclonal Antibody [Clone:4C6] |
|
E45M21592 |
EnoGene |
100 ug |
EUR 595 |
SARS-CoV-2 S Protein Mouse Monoclonal Antibody [Clone 4C6] |
|
E45M21592V-2 |
EnoGene |
50 ul |
EUR 195 |
SARS-CoV-2 S Protein Mouse Monoclonal Antibody [Clone:3A2] |
|
E45M21594 |
EnoGene |
100 ug |
EUR 595 |
SARS-CoV-2 S Protein Mouse Monoclonal Antibody [Clone 3A2] |
|
E45M21594V-2 |
EnoGene |
50 ul |
EUR 195 |
SARS-CoV-2 S1+S2 ECD (S-ECD) Protein Antibody ELISA Kit |
|
MBS9141991-5x96Tests |
MyBiosource |
5x96Tests |
EUR 3890 |
SARS-CoV-2 S1+S2 ECD (S-ECD) Protein Antibody ELISA Kit |
|
MBS9141991-96Tests |
MyBiosource |
96Tests |
EUR 845 |
SARS-CoV-2 S1+S2 ECD(S-ECD) Protein Antibody ELISA Kit |
|
RK04158 |
Abclonal |
96T |
EUR 513.66 |
SARS-CoV spike protein Antibody |
|
abx023139-100ug |
Abbexa |
100 ug |
EUR 1028.4 |
|
|
SARS-CoV Spike Protein Antibody |
|
abx023139-400l |
Abbexa |
400 µl |
Ask for price |
SARS-CoV Spike Protein Antibody |
|
abx023139-80l |
Abbexa |
80 µl |
EUR 1062.5 |
SARS-CoV spike protein Antibody |
|
abx023143-100ug |
Abbexa |
100 ug |
EUR 1028.4 |
|
|
SARS-CoV Spike Protein Antibody |
|
abx023143-400l |
Abbexa |
400 µl |
Ask for price |
SARS-CoV Spike Protein Antibody |
|
abx023143-80l |
Abbexa |
80 µl |
EUR 1062.5 |
SARS S-protein Antibody HRP Conjugated |
|
MBS9459771-01mL |
MyBiosource |
0.1mL |
EUR 595 |
SARS S-protein Antibody HRP Conjugated |
|
MBS9459771-5x01mL |
MyBiosource |
5x0.1mL |
EUR 2525 |
SARS S-protein Antibody FITC Conjugated |
|
MBS9459772-01mL |
MyBiosource |
0.1mL |
EUR 595 |
SARS S-protein Antibody FITC Conjugated |
|
MBS9459772-5x01mL |
MyBiosource |
5x0.1mL |
EUR 2525 |
Biotinylated SARS-CoV-2 S1+S2 ECD(S-ECD) Protein Antibody(DET) |
|
RM17606 |
Abclonal |
50μg |
EUR 364.88 |
Rabbit anti-COVID-19/SARS-CoV-2 S Protein Polyclonal Antibody |
|
E40PAV201 |
EnoGene |
N/A |
EUR 346.5 |
|
Description: N/A |
SARS-CoV-2 S2 Protein Antibody |
|
abx376525-96tests |
Abbexa |
96 tests |
EUR 243.75 |
SARS-CoV-2 S1 Protein Antibody |
|
abx376527-96tests |
Abbexa |
96 tests |
EUR 243.75 |
SARS-CoV-2 S4 Protein Antibody |
|
abx376528-96tests |
Abbexa |
96 tests |
EUR 243.75 |
SARS-CoV-2 S1 Protein Antibody |
|
abx376540-96tests |
Abbexa |
96 tests |
EUR 243.75 |
SARS-CoV-2 S2 Protein Antibody |
|
abx376541-96tests |
Abbexa |
96 tests |
EUR 243.75 |
SARS-CoV-2 S1 Protein Antibody |
|
abx229485-100g |
Abbexa |
100 µg |
EUR 350 |
SARS-CoV-2 M Protein Antibody |
|
abx229988-100g |
Abbexa |
100 µg |
EUR 312.5 |
SARS Spike Protein Polyclonal Antibody |
|
MBS191597-01mL |
MyBiosource |
0.1mL |
EUR 370 |
SARS Spike Protein Polyclonal Antibody |
|
MBS191597-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1650 |
SARS Spike Protein Polyclonal Antibody |
|
MBS191598-01mL |
MyBiosource |
0.1mL |
EUR 370 |
SARS Spike Protein Polyclonal Antibody |
|
MBS191598-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1650 |
SARS Spike Protein Polyclonal Antibody |
|
MBS191599-01mL |
MyBiosource |
0.1mL |
EUR 370 |
SARS Spike Protein Polyclonal Antibody |
|
MBS191599-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1650 |
SARS Spike Protein Polyclonal Antibody |
|
MBS191600-01mL |
MyBiosource |
0.1mL |
EUR 370 |
SARS Spike Protein Polyclonal Antibody |
|
MBS191600-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1650 |
SARS Spike Protein Polyclonal Antibody |
|
MBS191601-01mL |
MyBiosource |
0.1mL |
EUR 370 |
SARS Spike Protein Polyclonal Antibody |
|
MBS191601-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1650 |
SARS-CoV-2 ORF8 Protein Antibody |
|
abx376548-96tests |
Abbexa |
96 tests |
EUR 243.75 |
SARS-CoV-2 ORF8 Protein Antibody |
|
abx229999-100g |
Abbexa |
100 µg |
EUR 312.5 |
SARS Spike Protein Antibody (N-term) |
|
GWB-F06EAE |
GenWay Biotech |
0.1 mg |
Ask for price |
SARS Matrix Protein Polyclonal Antibody |
|
MBS191602-01mL |
MyBiosource |
0.1mL |
EUR 370 |
SARS Matrix Protein Polyclonal Antibody |
|
MBS191602-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1650 |
SARS Matrix Protein Polyclonal Antibody |
|
MBS191603-01mL |
MyBiosource |
0.1mL |
EUR 370 |
SARS Matrix Protein Polyclonal Antibody |
|
MBS191603-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1650 |
SARS-CoV-2 ORF7a Protein Antibody |
|
abx376547-96tests |
Abbexa |
96 tests |
EUR 243.75 |
SARS-CoV-2 Spike Protein Antibody |
|
abx229482-100g |
Abbexa |
100 µg |
EUR 1725 |
SARS-CoV-2 Spike Protein Antibody |
|
abx229483-100g |
Abbexa |
100 µg |
EUR 350 |
SARS-CoV-2 Spike Protein Antibody |
|
abx229484-100g |
Abbexa |
100 µg |
EUR 350 |
SARS-CoV-2 ORF7a Protein Antibody |
|
abx229998-100g |
Abbexa |
100 µg |
EUR 312.5 |
SARS-COV-2 Spike Protein Antibody |
|
C46148-100ul |
Assay Biotech |
100μl |
EUR 217 |
|
Description: SARS-COV-2 Spike Protein Rabbit Polyclonal Antibody |
SARS-COV-2 Spike Protein Antibody |
|
C46148-50ul |
Assay Biotech |
50μl |
EUR 143.5 |
|
Description: SARS-COV-2 Spike Protein Rabbit Polyclonal Antibody |
Anti SARS-CoV-2 (2019-nCoV) S protein RBD monoclonal antibody (F3C10) |
|
MBS1560487-005mg |
MyBiosource |
0.05mg |
EUR 275 |
Anti SARS-CoV-2 (2019-nCoV) S protein RBD monoclonal antibody (F3C10) |
|
MBS1560487-01mg |
MyBiosource |
0.1mg |
EUR 350 |
Anti SARS-CoV-2 (2019-nCoV) S protein RBD monoclonal antibody (F3C10) |
|
MBS1560487-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1250 |
SARS Envelope Protein Polyclonal Antibody |
|
MBS191604-01mL |
MyBiosource |
0.1mL |
EUR 370 |
SARS Envelope Protein Polyclonal Antibody |
|
MBS191604-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1650 |
SARS Envelope Protein Polyclonal Antibody |
|
MBS191605-01mL |
MyBiosource |
0.1mL |
EUR 370 |
SARS Envelope Protein Polyclonal Antibody |
|
MBS191605-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1650 |
SARS Membrane Protein Antibody (N-term) |
|
GWB-C88B00 |
GenWay Biotech |
0.1 mg |
Ask for price |
SARS Envelope Protein Antibody (C-term) |
|
GWB-7881EB |
GenWay Biotech |
0.1 mg |
Ask for price |
SARS-CoV-2 Membrane Protein Antibody |
|
abx376538-96tests |
Abbexa |
96 tests |
EUR 243.75 |
SARS-CoV-2 Envelope Protein Antibody |
|
abx226552-100g |
Abbexa |
100 µg |
EUR 243.75 |
SARS-CoV-2 Envelope Protein Antibody |
|
abx229987-100g |
Abbexa |
100 µg |
EUR 312.5 |
SARS-CoV-2 envelope protein Antibody |
|
MBS5401506-01mg |
MyBiosource |
0.1mg |
EUR 445 |
SARS-CoV-2 envelope protein Antibody |
|
MBS5401506-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1855 |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
abx024238-400l |
Abbexa |
400 µl |
Ask for price |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
abx024238-80l |
Abbexa |
80 µl |
EUR 1200 |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
abx024239-400l |
Abbexa |
400 µl |
Ask for price |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
abx024239-80l |
Abbexa |
80 µl |
EUR 1200 |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
abx243131-96tests |
Abbexa |
96 tests |
EUR 375 |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
abx243132-96tests |
Abbexa |
96 tests |
EUR 287.5 |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
abx376481-96tests |
Abbexa |
96 tests |
EUR 243.75 |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
abx376521-96tests |
Abbexa |
96 tests |
EUR 243.75 |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
abx376530-96tests |
Abbexa |
96 tests |
EUR 243.75 |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
abx376535-96tests |
Abbexa |
96 tests |
EUR 243.75 |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
abx229487-100g |
Abbexa |
100 µg |
EUR 1725 |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
abx229489-100g |
Abbexa |
100 µg |
EUR 350 |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
abx229490-100g |
Abbexa |
100 µg |
EUR 350 |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
abx229974-100g |
Abbexa |
100 µg |
EUR 312.5 |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
abx229975-100g |
Abbexa |
100 µg |
EUR 312.5 |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
abx229976-100g |
Abbexa |
100 µg |
EUR 325 |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M01A06C-100ug |
Absea Biotechnology |
100 ug |
EUR 280 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M01A06C-1mg |
Absea Biotechnology |
1 mg |
EUR 1400 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M01A06C-50ug |
Absea Biotechnology |
50 ug |
EUR 196 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M01H08C-100ug |
Absea Biotechnology |
100 ug |
EUR 280 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M01H08C-1mg |
Absea Biotechnology |
1 mg |
EUR 1400 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M01H08C-50ug |
Absea Biotechnology |
50 ug |
EUR 196 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M02D10C-100ug |
Absea Biotechnology |
100 ug |
EUR 360 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M02D10C-1mg |
Absea Biotechnology |
1 mg |
EUR 1800 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M02D10C-50ug |
Absea Biotechnology |
50 ug |
EUR 252 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M02D11C-100ug |
Absea Biotechnology |
100 ug |
EUR 280 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M02D11C-1mg |
Absea Biotechnology |
1 mg |
EUR 1400 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M02D11C-50ug |
Absea Biotechnology |
50 ug |
EUR 196 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M02F04C-100ug |
Absea Biotechnology |
100 ug |
EUR 280 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M02F04C-1mg |
Absea Biotechnology |
1 mg |
EUR 1400 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M02F04C-50ug |
Absea Biotechnology |
50 ug |
EUR 196 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M02G05C-100ug |
Absea Biotechnology |
100 ug |
EUR 280 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M02G05C-1mg |
Absea Biotechnology |
1 mg |
EUR 1400 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M02G05C-50ug |
Absea Biotechnology |
50 ug |
EUR 196 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M02G06C-100ug |
Absea Biotechnology |
100 ug |
EUR 280 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M02G06C-1mg |
Absea Biotechnology |
1 mg |
EUR 1400 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M02G06C-50ug |
Absea Biotechnology |
50 ug |
EUR 196 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M04A02C-100ug |
Absea Biotechnology |
100 ug |
EUR 280 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M04A02C-1mg |
Absea Biotechnology |
1 mg |
EUR 1400 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M04A02C-50ug |
Absea Biotechnology |
50 ug |
EUR 196 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M04D02C-100ug |
Absea Biotechnology |
100 ug |
EUR 280 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M04D02C-1mg |
Absea Biotechnology |
1 mg |
EUR 1400 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M04D02C-50ug |
Absea Biotechnology |
50 ug |
EUR 196 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M06G01C-100ug |
Absea Biotechnology |
100 ug |
EUR 280 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M06G01C-1mg |
Absea Biotechnology |
1 mg |
EUR 1400 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M06G01C-50ug |
Absea Biotechnology |
50 ug |
EUR 196 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M07A01C-100ug |
Absea Biotechnology |
100 ug |
EUR 280 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M07A01C-1mg |
Absea Biotechnology |
1 mg |
EUR 1400 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M07A01C-50ug |
Absea Biotechnology |
50 ug |
EUR 196 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M07A08C-100ug |
Absea Biotechnology |
100 ug |
EUR 280 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M07A08C-1mg |
Absea Biotechnology |
1 mg |
EUR 1400 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M07A08C-50ug |
Absea Biotechnology |
50 ug |
EUR 196 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M07E02C-100ug |
Absea Biotechnology |
100 ug |
EUR 280 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M07E02C-1mg |
Absea Biotechnology |
1 mg |
EUR 1400 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M07E02C-50ug |
Absea Biotechnology |
50 ug |
EUR 196 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M08H09C-100ug |
Absea Biotechnology |
100 ug |
EUR 280 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M08H09C-1mg |
Absea Biotechnology |
1 mg |
EUR 1400 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M08H09C-50ug |
Absea Biotechnology |
50 ug |
EUR 196 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M11D05C-100ug |
Absea Biotechnology |
100 ug |
EUR 280 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M11D05C-1mg |
Absea Biotechnology |
1 mg |
EUR 1400 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M11D05C-50ug |
Absea Biotechnology |
50 ug |
EUR 196 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M11H07C-100ug |
Absea Biotechnology |
100 ug |
EUR 280 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M11H07C-1mg |
Absea Biotechnology |
1 mg |
EUR 1400 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M11H07C-50ug |
Absea Biotechnology |
50 ug |
EUR 196 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M13A02C-100ug |
Absea Biotechnology |
100 ug |
EUR 280 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M13A02C-1mg |
Absea Biotechnology |
1 mg |
EUR 1400 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M13A02C-50ug |
Absea Biotechnology |
50 ug |
EUR 196 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M15F09C-100ug |
Absea Biotechnology |
100 ug |
EUR 280 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M15F09C-1mg |
Absea Biotechnology |
1 mg |
EUR 1400 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M15F09C-50ug |
Absea Biotechnology |
50 ug |
EUR 196 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M16E03C-100ug |
Absea Biotechnology |
100 ug |
EUR 280 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M16E03C-1mg |
Absea Biotechnology |
1 mg |
EUR 1400 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06251M16E03C-50ug |
Absea Biotechnology |
50 ug |
EUR 196 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06255M10D12C-100ug |
Absea Biotechnology |
100 ug |
EUR 280 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06255M10D12C-1mg |
Absea Biotechnology |
1 mg |
EUR 1400 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06255M10D12C-50ug |
Absea Biotechnology |
50 ug |
EUR 196 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06255W11H06C-100ug |
Absea Biotechnology |
100 ug |
EUR 280 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06255W11H06C-1mg |
Absea Biotechnology |
1 mg |
EUR 1400 |
|
|
|
Description: Monoclonal Antibody |
SARS-CoV-2 Nucleocapsid Protein Antibody |
|
K06255W11H06C-50ug |
Absea Biotechnology |
50 ug |
EUR 196 |
|
|
|
Description: Monoclonal Antibody |
We show RhAd52 vaccines elicit sturdy SARS-CoV-2-specific antibody responses and defend in opposition to medical illness and viral replication within the lungs. Additional, binding and neutralizing antibody titers correlated with protecting efficacy. These information validate the MA10 mouse mannequin as a useful gizmo to display screen and research novel vaccine candidates, in addition to the event of RhAd52 vaccines for COVID-19.